Sensorion Reports the Completion of Patient Recruitment in P-I/II (Audiogene) Gene Therapy Clinical Trial
Shots:
- Sensorion has completed patient recruitment for the first cohort (3 patients) of P-I/II (Audiogene) study, with the third patient receiving SENS-501 gene therapy in Dec 2024
- The P-I/II study will assess safety, tolerability & efficacy of SENS-501 for OTOF gene-mediated hearing loss in infants aged 6-31mos., in 2 dose-escalation cohorts and an expansion cohort, with safety as 1EP and auditory brainstem response (ABR) as the efficacy EP. The trial will also assess the efficacy of Sensorion's delivery system
- SENS-501 is a gene therapy targeting congenital deafness caused by OTOF gene mutations. It delivers a functional OTOF gene to hair cells via AAV technology to restore hearing by enabling normal sound-to-signal conversion
Ref: BusinessWire| Image: Sensorion
Related News:- Sensorion Concludes Patient Enrolment in the P-IIa Study of SENS-401 for Residual Hearing Preservation After Cochlear Implantation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
